加格列淨
加格列淨（分子式：C25H29ClO6，化學名：(1S)-1,5-脫水-1-C-[3-[4-[(1α,3α,5α)-雙環[3.1.0]己-3-基氧基]苄基-4-氯苯基]-D-葡萄糖醇）是一種由四環醫藥研發的實驗性SGLT2抑制劑，[1]用於治療糖尿病。[2]
 | |
| 法律規範狀態 | |
|---|---|
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 1800115-22-3  |
| UNII | |
| 化學資訊 | |
| 化學式 | C25H29ClO6 |
| 摩爾質量 | 460.95 g·mol−1 |
| 3D模型（JSmol） | |
| |
它可以2-氯-5-溴苯甲酸和3-環戊烯-1-醇為原料，經多步反應製得。[3]
參考文獻
編輯- ^ Song, Ling; Yao, Xueting; Liu, Yang; Zhong, Wen; Jiang, Ji; Liu, Hongzhong; Zhou, Huimin; Shi, Chongtie; Zong, Kaiqi; Wang, Chong; Ma, Chuanxiang; Liu, Dongyang; Hu, Pei. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European Journal of Pharmaceutical Sciences. April 2020, 147: 105281. doi:10.1016/j.ejps.2020.105281.
- ^ 惠升生物加格列净片. 四環醫藥. [2023-12-14]. （原始內容存檔於2023-12-14）.
- ^ Wu, Frank. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus). 2015. EP2891654.